OBIO · NASDAQ
Orchestra BioMed Holdings, Inc.
$5.11 -0.85 (-14.26%)
Company overview
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also include FreeHold retractors, which are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $307M
- Employees
- 70
- Headquarters
- New Hope, PA
- Website
- orchestrabiomed.com
- CEO
- David Hochman
- Listed
- August 4, 2020
- P/E
- -3.60
- Dividend yield
- 0.00%
Company financials
- Revenue
- $32.7M
- Gross profit
- $32.5M
- Operating income
- -$55M
- EBITDA
- -$54.4M
- Net income
- -$54.6M
- EPS
- -$1.42
- Total assets
- $101M
- Total debt
- $33.6M
- Gross margin
- 99.27%
- Net margin
- -166.96%
- Earnings yield
- -27.79%
No geographic segmentation.
Showing FY 2025
OBIO
1D
NASDAQ
O5.82H6.16L5.75C6.00+0.44 (+7.91%)Vol335.41K
News